{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-014273","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.498976+00:00","generated_at":"2026-06-23T22:12:28.380904+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precigen completes sale of Trans Ova Genetics for $170M upfront plus up to $10M earn-out","bullets":["Sale closed on August 18, 2022; buyer is Spring Bidco LLC (URUS). Net proceeds ~$169.5M after adjustments.","Company plans to use $200M (including proceeds) to pay senior convertible notes and for other permitted purposes.","Up to $10M earn-out based on Trans Ova performance in 2022-2023, payable in cash.","Divestiture allows Precigen to focus on its core gene and cell therapy pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-014273","json":"https://secwatch.observer/filing/0000950103-22-014273.json","markdown":"https://secwatch.observer/filing/0000950103-22-014273.md","text":"https://secwatch.observer/filing/0000950103-22-014273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322014273/0000950103-22-014273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322014273/dp178880_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:12:28.380904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}